Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Partially Remote

Drugs

Locations

Clinical Specialty

361-380 of 998 trials

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemotePediatricsRheumatology

DZR123 for Advanced Solid Tumors and Lymphomas

We are studying a new treatment called DZR123 for patients with advanced solid tumors and lymphomas. The trial will help us understand its safety and how well it works alone and with another medication.

Advanced Solid Tumors and Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)No Placebo Investigational Medicines Partially RemoteOncology

Endometrial Cancer: New Treatment Combinations

We are studying whether a new combination of Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab is more effective than standard chemotherapy for patients with advanced or recurrent HER2-expressing endometrial cancer.

Endometrial CancerConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteGynecology and ObstetricsOncology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteNeurologyPediatrics

Atopic Dermatitis: Amlitelimab Treatment Study

We are studying two dosing schedules of amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if it helps maintain treatment response compared to stopping treatment.

Atopic Dermatitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

COVID-19 Treatment: Anti-Coronavirus Immunoglobulin Study

We are testing a new immunoglobulin treatment for adults recently diagnosed with COVID-19 to see if it improves health outcomes compared to a placebo. This study aims to understand its safety and effectiveness alongside standard care.

COVID-19≤3 monthsConfirmation phase (III)6-10 visits Investigational Medicines Partially RemoteInfectious DiseasesInternal Medicine

Long-Term Follow-Up of CAR T-Cell Therapy Patients

We are studying the long-term effects and safety of CAR T-cell therapy in patients who have received this treatment. This includes monitoring for delayed side effects and the persistence of modified T-cells in the blood.

Multiple MyelomaB-cell LymphomaB-cell Type Acute Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteHematologyOncology

Methylprednisolone for Infants with Neuroendocrine Cells Hyperplasia

We are studying whether methylprednisolone pulses can reduce the need for oxygen therapy in infants with NEHI. The trial also examines the treatment's effects on respiratory health and quality of life.

Neuroendocrine Cell Hyperplasia of Infancy>2 yearsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Partially RemoteInternal MedicinePulmonology

Alpha-1 Antitrypsin Deficiency Emphysema: SAR447537 Study

We are studying the long-term safety of SAR447537 in adults with alpha-1 antitrypsin deficiency emphysema. The trial will also evaluate its effects on lung health and how the body processes the treatment.

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema>2 yearsEfficacy phase (II)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Thrombosis Prevention in Surgery: Apixaban Study

We are studying whether the medication apixaban can help prevent blood clots in patients undergoing general abdominal, gynecologic, and urologic surgeries. This trial compares its effects to not using any anticoagulants during surgery.

Venous Thromboembolism>2 yearsMonitoring phase (IV)Standard Medicines Partially RemoteGynecology and ObstetricsInternal MedicineOrthopedics and TraumatologyUrology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Partially RemoteCardiologyInternal Medicine

Fragile X Syndrome: Long-Term Study of ZYN002 Gel

We are examining the long-term safety and tolerability of a gel medication for children and young adults with Fragile X Syndrome. This study includes participants who have previously used the medication and are continuing to see if it helps manage their symptoms.

Fragile X Syndrome≤3 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteInternal MedicineNeurologyPediatrics

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Standard Medicines Partially RemoteCardiologyInternal Medicine

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNephrologyPediatrics

MDMA-Assisted Therapy for Treatment-Resistant PTSD

We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.

Posttraumatic Stress Disorder6-12 monthsEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Partially RemotePsychiatry

HER3-Targeted Imaging with Patritumab Deruxtecan

We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.

EGFR Mutation Positive Advanced Lung Cancer>2 yearsEfficacy phase (II)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurologyOncology

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Advanced Solid Tumors: AZD0901 Treatment Study

We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.

Gastric CancerGastroesophageal Junction CancerPancreatic Ductal AdenocarcinomaSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOncology

Search Clinical Trials in the European Union